14
Treatment
Table A2: Immunosuppressive Agents
Immunosuppressive
Agents Dosing Indications
Sulfasalazine
(nonselective
immuno-suppressant)
Initial: 500 mg once daily or 1 g/day
in 2 divided doses; increase weekly
to maintenance dose: 2 g/day in 2
divided doses; maximum: 3 g/day (if
response to 2 g/day is inadequate aer
12 weeks of treatment)
Mild or moderate
inflammatory
arthritis
Tofacitinib ( Janus
kinase inhibitor)
10 mg PO bid for 30 days Colitis
refractory to all
immunosuppression
treatments
Table A3. Commonly Conducted Testing at Baseline Prior to
ICPi Therapy*
Clinical
Physical examination including PS, weight, BMI, HR & BP, SPO
2
Comprehensive history including autoimmune, organ-specific disease, endocrinopathy,
neuropathy, and infectious disease
Comprehensive systems review should be performed with specific attention to bowel
habits, respiratory symptoms, skin rash, arthralgias, and neurologic symptoms.
Laboratory
Complete CBC + DIFF
Complete metabolic panel that may include serum electrolytes (Na, K, Ca, CO
2
), liver
function (AST, ALT, ALKP, GGT), creatinine, CK, total bilirubin, glucose
TSH, free T4
Imaging/Other testing
Chest X-ray
CT
Electrocardiogram
* Other testing may also be necessary, based on patient's history and pre-existing comorbidities and/
or risk factors.
(cont'd)
